We are live on ! Find out more
CHRS icon

Coherus Oncology
CHRS

176 hedge funds and large institutions have $572M invested in Coherus Oncology in 2022 Q2 according to their latest regulatory filings, with 24 funds opening new positions, 74 increasing their positions, 53 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

534% more call options, than puts

Call options by funds: $3.17M | Put options by funds: $499K

40% more repeat investments, than reductions

Existing positions increased: 74 | Existing positions reduced: 53

3.53% more ownership

Funds ownership: 98.39% → 101.92% (+3.5%)

4% less funds holding

Funds holding: 183 → 176 (-7)

11% less first-time investments, than exits

New positions opened: 24 | Existing positions closed: 27

41% less capital invested

Capital invested by funds: $975M → $572M (-$403M)

Holders
176
Holders Change
-7
Holders Change %
-3.83%
% of All Funds
2.96%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
24
Increased
74
Reduced
53
Closed
27
Calls
$3.17M
Puts
$499K
Net Calls
+$2.67M
Net Calls Change
+$3.27M

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$10.6M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$9.37M
3
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
+$7.73M
4
BlackRock
BlackRock
New York
+$7.05M
5
TLP
Tri Locum Partners
New York
+$3.27M

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$9.13M
2
Swedbank
Swedbank
Sweden
-$6.97M
3
TSW
Thompson Siegel & Walmsley
Virginia
-$6.06M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.98M
5
EAM
Eagle Asset Management
Florida
-$3.14M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$4.19M -$154K -17,734 -3%
D.E. Shaw & Co
27
D.E. Shaw & Co
New York
$3.96M +$1.57M +180,878 +49%
Charles Schwab
28
Charles Schwab
California
$3.45M +$73.8K +8,492 +2%
Principal Financial Group
29
Principal Financial Group
Iowa
$3.41M -$175K -20,141 -4%
Macquarie Group
30
Macquarie Group
Australia
$3.12M – – –
Millennium Management
31
Millennium Management
New York
$2.82M +$1.63M +187,245 +93%
Nordea Investment Management
32
Nordea Investment Management
Sweden
$2.77M +$225K +25,849 +7%
TLP
33
Tri Locum Partners
New York
$2.73M +$3.27M +376,486 New
Invesco
34
Invesco
Georgia
$2.41M +$38.8K +4,465 +1%
PFC
35
Phocas Financial Corp
California
$2.29M -$587K -67,555 -18%
VOYA Investment Management
36
VOYA Investment Management
Georgia
$2.18M +$2M +229,447 +318%
CS
37
Credit Suisse
Switzerland
$1.83M +$353K +40,563 +19%
DGI
38
Disciplined Growth Investors
Minnesota
$1.78M +$9.56K +1,100 +0.4%
Rafferty Asset Management
39
Rafferty Asset Management
New York
$1.67M -$367K -42,181 -15%
Bank of America
40
Bank of America
North Carolina
$1.54M -$295K -33,955 -14%
Renaissance Technologies
41
Renaissance Technologies
New York
$1.49M +$360K +41,400 +25%
CM
42
CM Management
Florida
$1.45M +$435K +50,000 +33%
GCM
43
Graham Capital Management
Connecticut
$1.41M +$1.46M +168,105 +615%
DMKJ
44
David M. Knott Jr
$1.35M +$596K +68,579 +58%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$1.3M +$132K +15,203 +9%
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
46
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Ontario, Canada
$1.3M +$1.56M +179,800 New
Tudor Investment Corp
47
Tudor Investment Corp
Connecticut
$1.27M -$118K -13,611 -7%
PAMS
48
Pictet Asset Management (Switzerland)
Switzerland
$1.22M +$382K +43,889 +35%
BCC
49
Bridge City Capital
Oregon
$1.17M -$2.49K -286 -0.2%
Hudson Bay Capital Management
50
Hudson Bay Capital Management
Connecticut
$1.12M +$1.35M +155,000 New
1
2
3 4 5

CHRS Hedge Fund Activity: Q2 2022 in Review

176 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q2 2022, worth a combined $572M — down 41% from $975M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of CHRS and 24 opened new positions — a net loss of 3 holders — while 53 trimmed existing stakes and 74 added.

The largest buyer was State Street, adding an estimated $10.6M. The largest seller was Perceptive Advisors, cutting an estimated $9.13M.

  • 176 institutional investors held Coherus Oncology (CHRS) as of Q2 2022, down from 183 in Q1 2022.
  • Funds reported $572M of Coherus Oncology stock for Q2 2022, down 41% quarter-over-quarter.
  • 24 funds opened new Coherus Oncology positions in Q2 2022 and 27 closed out, a net change of -3 holders.
  • The largest Coherus Oncology buyer in Q2 2022 was State Street, an estimated $10.6M added.
  • The largest Coherus Oncology seller in Q2 2022 was Perceptive Advisors, an estimated $9.13M sold.

Based on aggregated 13F filings for Q2 2022.